Industry Insight | New Target Identified for CAR-NK Therapy in Acute Myeloid Leukemia

April 2026 - Researchers and biotechnology companies continue to expand the potential of natural killer (NK) cell therapies as new targets and engineering strategies emerge. Recently, Precision Biologics announced the discovery of a novel glycan-based target that could support the development of next-generation CAR-NK therapies for acute myeloid leukemia (AML).

The company reported that the target is associated with truncated core-1 O-glycans, which are expressed in several AML subtypes. According to the company, targeting these structures may allow engineered immune cells to selectively recognize malignant cells while minimizing damage to healthy tissues.

Photo by CDC on Unsplash

Data related to the discovery were presented at the American Association for Cancer Research Annual Meeting, highlighting the growing interest in applying glycan biology to next-generation immunotherapies.

In parallel, recent research has also identified key intracellular regulators that influence NK cell proliferation and function. Using genome-wide CRISPR screening, scientists mapped several genes that limit NK cell activity in the tumor microenvironment. Removing or modifying these regulators significantly enhanced NK-cell-mediated tumor killing in experimental models.

Photo by National Cancer Institute on Unsplash

Together, these findings reflect a broader industry trend: the rapid evolution of NK-based immunotherapies from early experimental concepts to increasingly sophisticated engineered platforms.

However, as more CAR-NK programs enter clinical development, researchers note that manufacturing scalability and efficient NK cell expansion remain critical challenges for the field. Reliable cell expansion platforms, feeder systems, and scalable manufacturing processes will play an essential role in supporting the next wave of NK-based therapies.

Sources:

Precision Biologics announcement and data presented at American Association for Cancer Research Annual Meeting

Genome-wide CRISPR screening study on NK cell regulation